Study Design. The study was based on porcine posterolateral fusion model. Objective. The study aims to prove that polyelectrolyte complex (PEC) carrier could enhance the efficacy and safety profile of bone morphogenetic protein-2 (BMP-2). Summary of Background Data. BMP-2 was introduced to enhance posterolateral fusion; however, extremely high doses of this molecule were often used which contributed to various complications. This was attributed to the poor modulation capacity of the traditional carrier absorbable collagen sponge (ACS). To reduce the efficacious dose of BMP-2 and its associated complications, heparin-based PEC was introduced. Methods. L3/L4 and L5/L6 two-level posterolateral spinal fusion was performed on six pigs using two doses of BMP-2 with PEC or ACS: (1) PEC with 800 mg BMP-2 (n ¼ 2); (2) PEC with 400 mg BMP-2 (n ¼ 2); (3) ACS with 800 mg BMP-2 (n ¼ 1); (4) ACS with 400 mg of BMP-2 (n ¼ 1). The construct was loaded into a rigid bioabsorbable cage for implantation. Fusion rate and quality were assessed 2 months after operation.
P osterolateral fusion surgery is commonly employed in the treatment of degenerated and potentially unstable spinal motion segments. 1 Although readily accessible at surgery, achieving solid fusion in the posterolateral gutter is technically and biologically challenging given the magnitude of multidirectional tensile forces acting at this site and therefore the risk of micromotions and instabilities. 2 In addition, this is a potentially compromised vascular bed as the established networks of blood vessels were originally intended for supplying muscles and other soft connective tissues rather than bone. Indeed, fusion failure rates as high as 55% has been documented in uninstrumented posterolateral fusion. 3 Implantation of autologous bone tissue grafts harvested commonly from the iliac crest has become ''gold standard'' practice to address the challenges in posterolateral fusion. Comorbidities such as chronic pain at donor site, prolonged surgery time, and increased risk of blood loss, however, continue to be limitations of this strategy. 4, 5 In addition, outcome inconsistency owing to variations in the quality and quantity of harvestable bone tissue remains a relevant drawback. 6 These issues have driven research aimed at developing bone graft substitutes including osteoinductive bioactive molecules. 4 Over a decade ago, bone morphogenetic protein-2 (BMP-2) loaded onto absorbable collagen sponge (ACS), was given regulatory clearance for use in single-level anterior lumbar interbody fusion. Subsequently, BMP-2 has been applied both on-and off-labeled reaching nearly 25% of spinal fusion surgeries in the USA alone. 7 Association with complications such as seroma, heterotopic ossification, radiculitis, osteolysis, and retrograde ejaculation continues to be documented. [8] [9] [10] Recently, Carragee et al 11 reported that the rate of new cancer events in patients treated with a formulation of BMP-2 was six times as high as in bone graft-treated patients. It was presumed that the use of extremely large amount of this highly potent growth factor, necessitated by the inefficiencies of ACS carrier vehicle, might underscore these complications. 11 Therefore, defining optimal dosing and carrier vehicles for BMP-2 is recognized as critical to enhancing the safety profile of BMP-2 in spinal fusion. 10 The endogenous role of proteoglycans such as heparin and heparan sulfate in stabilizing and protecting the bioactivity of labile cytokines including BMP-2 against the actions of endogenous antagonists such as noggin has been elucidated. 12 In this regard, heparin-doped polyelectrolyte complex (PEC) was shown to sequester and control BMP-2 release and further enhance the therapeutic efficiency of BMP-2 in vivo. 13, 14 Further questions, however, remain before broader clinical application of this new carrier strategy can be envisaged in a more challenging large animal posterolateral fusion model. This study was designed to address three questions: (1) Whether BMP-2 delivered by PEC could induce spinal fusion in a porcine posterolateral fusion model; (2) Whether PEC carrier could enhance therapeutic efficiency of BMP-2 and reduce complications when compared to ACS; (3) Whether the quality of newly formed bone in PEC groups is comparable or superior to that in ACS groups.
MATERIALS AND METHODS

Materials
Bioresorbable poly(e-caprolactone)-20% tricalcium phosphate (PCL/TCP) was used as the compression-resistant scaffold (Osteopore, Singapore). 15 The scaffolds employed as cages in this study exhibited 80% porosity, 100% pore interconnectivity, 0/90 degrees lay-down pore pattern, 350 to 500 mm pore size range, approximately 500 mm strut diameter, and (40 Â 20 Â 4) mm 3 in volume. Clinical grade BMP-2 (Medtronic Sofarmor Danek, Memphis, TN) was reconstituted at a concentration of 1.5 mg/mL. Ultrapure medium viscosity alginate was procured from Novomatrix (FMC Biopolymer, Princeton, NJ). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
Fabrication of Polyelectrolyte Complex
Alginate was gamma irradiated (8 mrad) and then dissolved in deionized water to obtain 4% (w/v) solution. A microbead generator (Nisco Engineering AG, Zü rich, Switzerland) was used to fabricate alginate microbeads according to the protocol reported previously. 13 The polycation layer was coated by suspending microbeads in 0.1% (w/v) poly-L-lysine solution for 15 minutes. Subsequently the polyanion coating layer was applied by suspending microbeads in 0.5% (w/v) heparin solution for 15 minutes. The alginate-PEC microbeads were loaded into the pores of a PCL/TCP scaffold (40 Â 20 Â 4) mm 3 . BMP-2 was then dripped onto PCL/TCP scaffolds loaded with microbeads and incubated overnight at 48C.
Surgical Procedure
Six male SPF Yorkshire pigs (average weight 50-60 kg; average age 6 months) were used. All animal-related procedures were preapproved by the institutional ethics review committee. The animals were divided into four groups, namely:
(1) PEC with 800 mg BMP-2 (n ¼ 2); (2) PEC with 400 mg BMP-2 (n ¼ 2); (3) ACS with 800 mg BMP-2 (n ¼ 1); (4) ACS with 400 mg of BMP-2 (n ¼ 1).
These animals underwent posterolateral fusion at the levels of L3/L4 and L5/L6. Each level has two fusion segments between the adjacent transverse processes. Therefore, there are eight intertransverse fusion segments each in groups 1 and 2 (equivalent to PEC groups in further discussion) (N ¼ 2; n ¼ 8) and four intertransverse fusion segments each in groups 3 and 4 (equivalent to ACS groups in further discussion) (N ¼ 1; n ¼ 4). The transverse processes of lumbar spine were exposed using a retroperitoneal approach through a paramedian incision from both sides. The scaffolds were fixed by PDS II (polydioxanone) Suture (Ethicon, Somerville, NJ) to bridge the adjacent transverse processes (Figure 1 A, B) . No spinal instrumentation was performed. Prophylactic antibiotics (enrofloxacin 2.5 mg/kg) and analgesic (ketorolac tromethamine, 1 mg/kg) were administered after surgery. The pigs were allowed to mobilize freely without external mobilization. Animals were euthanized with an overdose of pentobarbital injected intravenously 2 months after surgery. The spinal segments areas of interest were harvested. Manual palpation was performed to assess the fusion quality.
Micro-Computed Tomography
The microstructure of the explanted spines was evaluated using the Quantum Fx micro-computed tomography (micro-CT) system (PerkinElmer, Waltham, MA). The spine specimens were scanned at 30 mm voxel resolution with an integration time of 3 minutes. Imaging data were used for 3D image reconstruction employing 3D Studio Max software 1.2 (Volume Graphics GmBH, Heidelberg, Germany). The region of interest was randomly selected from newly formed bone tissue. One out of ten images was selected with polygon tool from the image stack and they were interpolated by CTan software. A total of 50 images were selected from each sample. Selected area was segmented with an optimized density threshold tool for bony structural analysis. The 3D structural parameters of the newly formed bone were calculated by CTan: bone volume/total volume (BV/TV), bone surface/BV (BS/BV), BS/TV, trabecular thickness (Tb. Th.), trabecular number (Tb.N.), trabecular separation (Tb. Sp.). 16 Radiographic fusion score was based on the bony bridging at the sagittal cuts of the micro-CT imaging: 0, no fusion; 1, fusion bridges less than 1 / 2 of the inter-transverse space; 2, fusion bridges more than 1 /2 of the intertransverse space but not complete bridging; 3, fusion completely bridges the intertransverse space. Two individuals were involved to assess the radiographic fusion score.
HISTOLOGY
Tissue sections were then stained with methylene blue and basic fuchsin metachromatic dyes. Histology slide was imaged under optical microscope (Olympus IX71, Tokyo, Japan). Eight images were randomly selected from each group within the fusion mass (n ¼ 8). Image J (National Institute of Health, Bethesda, MD) and Adobe Photoshop (Adobe Systems Inc., San Jose, CA) were used to measure static bone histomorphometric parameters. 17 Photographs of histology were used to generate black and white image masks, representing bone and nonbone tissue, respectively. Mineralized area ratio was calculated by dividing total area with methylene blue stained area. 16, 18, 19 
Statistical Analysis
Experimental results are reported as means AE standard deviation. One-way analysis of variance test was used to evaluate statistical difference. OriginPro 9.0 (OriginLab Corp, Northampton, MA) was used for graphing and data analysis and P < 0.05 was considered statistically significant.
RESULTS
Manual palpation revealed successful posterolateral fusion as the scaffolds were rigidly fixed to both the cephalic and caudal transverse processes in both PEC and ACS groups. There was no detectable motion in flexion/extension, lateral bending, and axial rotation in all segments operated on. Although manual palpation demonstrated fusion in all groups regardless of the carrier, radiological fusion score obtained from PEC groups was higher than that from ACS groups ( Table 1) . Micro-CT and histological examination ( Figure 2 A-P and 3) of the harvested tissue revealed that although there was formation of new bone in all groups, the newly formed bone in groups 1 and 2 was localized and contained within the scaffold and between the adjacent transverse processes. In comparison, there was violation of nearby anatomical structures such as the psoas muscle and neural foramen in groups 3 and 4. The fusion mass was visibly disorganized with large heterotopic bone formation observed beyond the scaffold and extending anteriorly beyond the borders of transverse processes thus invading the psoas muscles. Although there was a smooth transition between the newly formed mineralized tissue within the scaffold and the host bone bed of the transverse processes, with no demarcating fissures in groups 1 and 2, large gaps were observed in groups 3 and 4 suggestive of poor integration and partial detachment between newly formed bone tissue and the recipient transverse process fusion bed. In addition, the scaffolds were uniformly colonized with mineralized tissue in groups 1 and 2, whereas groups 3 and 4 showed areas of patchy translucency suggestive of nonuniformity in mineralized tissue deposition. This is consistent with heterotopic ossification and poor integration of newly formed bone into native bone noted previously. A comparison of group 1 to group 2 revealed that group 2 exhibited superior localization of the newly formed bone without compromising the fusion quality.
Photomicrographs in Figure 3 are representative microscopic images of methylene blue and basic fuchsin-stained tissue sections from all experimental groups at 8 weeks. Microstructure of the newly formed bone in groups 1 and 2 appeared visibly superior to that in groups 3 and 4. Healthy trabecular bone intertwining the porous spaces of the scaffold between the microfilaments could be observed in groups 1 and 2. On comparison, trabecular bone appeared to be thin and sparse in groups 3 and 4. The histomorphometric analysis indicated that the mineralized area ratio in groups 1 and 2 was 
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Heparin-Based PEC Enhances the Therapeutic Efficacy of BMP-2 Wang et al significantly higher than that in groups 3 and 4 ( Figure 4 ). This finding was confirmed by high-resolution micro-CT and 3D microarchitecture analysis (Figures 5 and 6 ). Quantitative data showed that BV/TV, BS/TV, Tb.Th., and Tb.N. in groups 1 and 2 were generally higher than that in groups 3 and 4. BS/BV in group 2 was significantly lower than that in group 4. Groups 1 and 2 had lower Tb.Sp. compared with groups 3 and 4. These findings indicate superior microarchitecture of the newly formed bone when delivered by PEC.
DISCUSSION
In this study, BMP-2 delivered by PEC in a compressionresistant scaffold was able to induce successful posterolateral fusion in porcine model. Furthermore, PEC also enhanced therapeutic efficiency of BMP-2. When BMP-2 was used with PEC compared with ACS, heterotopic ossification was minimized and microarchitecture of the newly formed bone tissue was also improved.
Contemporary standard doses of BMP-2 (1.5 mg/mL) with ACS approved for anterior lumbar interbody fusion failed to induce clinically significant amount of bone when used for posterolateral fusion in a rhesus monkey model. 20 This was attributed to compression from paraspinal muscle and premature loss of fusion material and volume. Khan et al 21 reported almost complete resolution of ACS by 4th week of implantation. It was concluded that it is critical to maintain the growth factor, carrier, and bulking agent in the fusion cascade until the bridging of the intertransverse processes. These findings underlined the importance of carrier and cage when delivering BMP-2 in the challenging posterolateral fusion environment. In this respect, numerous studies have explored diverse methods in achieving consistent posterolateral fusion using different fusion constructs to deliver bioactive molecules in various animal models. [21] [22] [23] Taken together, the ''ideal'' fusion construct would include an efficient carrier to sufficiently retain BMP-2 at fusion bed and prevent its premature degradation and elusion, and a cage to resist the compression from paraspinal muscle and also maintain adequate volume for fusion. In the present study, the performance of new carrier PEC to deliver BMP-2 in a compression-resistant PCL/TCP scaffold was evaluated in porcine posterolateral fusion model.
The first finding of this study is that BMP-2 delivered by heparin-based PEC in a compression-resistant scaffold successfully induced posterolateral spinal fusion in a large animal model. Manual palpation, CT scan, and histological examination indicate that newly formed bone tissue bridges the intertransverse processes in PEC groups. This is consistent with results of previous studies that demonstrated the use of this heparin-based PEC to achieve control release of BMP-2 in vitro and to successfully deliver this delicate growth factor in vivo in rodent and porcine models. 14, 24 PEC was fabricated using layer by layer self-assembly concept with heparin being the key component. It has been described in multiple studies that heparin has high affinity for BMP-2 and also stabilizes BMP-2's bioactivity. Ruppert et al 25 described that BMP-2 contains a heparin-binding domain at its N-terminal ends. Further study demonstrated that heparin was able to improve BMP-2 bioactivity in vitro and enhance its osteogenic capacity in vivo by prolonging its half-life and reducing inhibitory effects of antagonist such as noggin.
12,26,27 PEC alone could not induce any new bone formation. The key components of PEC which are alginate, poly-L-lysine, and heparin have no osteoinductive capacity. Although PEC without BMP-2 was not studied in current fusion model, we have tested PEC in both rodent posterolateral fusion and porcine anterior interbody fusion model previously and the result suggested that PEC alone without BMP-2 might not have significant osteogenic effect as no new bone formation was detected. 13, 14, 28, 29 It was further demonstrated in the present study that the therapeutic efficiency of BMP-2 was enhanced by PEC and the heterotopic ossification was grossly reduced in PEC groups compared with ACS groups. With same BMP-2 dose, the radiographic fusion score of the PEC groups was higher than that of ACS groups. The new bone induced by BMP-2/ PEC construct was well integrated into the native bone on transverse process without any visible fissure or gap. Patchy translucency within the scaffold and detachment of newly formed bone from the transverse processes were, however, observed in ACS groups. This might be due to insufficiency of the BMP-2 dose used in the ACS groups. Indeed, only 800 and 400 mg of BMP-2 per side were used in groups 3 and 4, whereas it was reported that at least 3000 mg of BMP-2 per side was required ACS carriers for high-order animal models of posterolateral fusion. 30, 31 Although 800 mg of BMP-2 was therapeutically insufficient to completely bridge the inter-transverse space in the present study, heterotopic ossification below the transverse processes and extending to the psoas muscles complicated the ACS groups. This corroborates with the well-reported burst release profile of BMP-2 from ACS due to low affinity and fast collagen degradation in vivo. It was reported that almost 50% of BMP-2 was released in the first 24 hours and around 90% was released in the following 10 days. [32] [33] [34] This initial burst release has several deleterious impacts. Firstly, it could induce high, though transitory, concentrations of this very powerful growth factor within the fusion bed. This has been shown to increase the osteoclastic activities thereby increasing bony resorption. 35 In fact, increased osteoclastic activities induced by transient high concentration of BMP-2 have been associated with abnormal histological structures within the newly formed trabecular bone such as cystic lesions and extensive adipose tissue distributions. 36 Secondly, given the relatively weak affinity of ACS for BMP-2, large amounts of BMP-2 could rapidly diffuse out of the intended fusion bed into surrounding tissue which could potentially cause ectopic bone formation. 37 Thirdly, to compensate for the inevitable initial loss in the burst release, large amounts of BMP-2 are often used to induce clinically significant fusion with ACS carriers. These might cause or at least exacerbate various complications such as heterotopic bone formation, seroma formation, radiculitis, retrograde ejaculation, and cancer risk. 11, [38] [39] [40] Heparin-based PEC carriers could overcome these shortcomings of ACS by avoiding initial burst release, retaining sufficient levels of BMP-2 at fusion beds, and further preventing extravasation into surrounding structures and protecting this labile biomolecule from degradation. 12, 28 Compared with ACS, PEC could effectively retain BMP-2 and only 40% of this growth factor was sustainably released in the initial 4 weeks. In addition, our previous studies in a rodent model highlighted the safety and efficacy potentials of BMP-2/PEC in spinal fusion as it enhanced the therapeutic efficiency allowing the use of lower doses of BMP-2 to achieve consistent fusion with no compromise in the rate of fusion.
14 Heparin-based PEC also enabled concurrent reduction in the incidence and extent of BMP-2-induced complications such as heterotopic bone formation and seroma formation. In the present study, when delivered by PEC, BMP-2 doses as low as 400 mg per side per level was able to induce fusion both clinically and radiographically. The newly formed bone tissue in PEC groups was well integrated into the scaffold and the adjacent transverse processes with minimal overgrowth. In comparison, it was reported that as much as 10 mg of BMP-2 per side per level (representing a 25-fold difference) was required to achieve clinical fusion in rhesus monkey posterolateral fusion. 41 In another report, 40 mg (2 mg/mL) of BMP-2 (representing a 100-fold difference) was used in a singlelevel posterolateral fusion in human clinical trial. 42 In this aspect, PEC might enhance the safety profile of BMP-2 by reducing the efficacious dosage and its related complications and widen the clinical application of BMP-2.
Last but not least, the microarchitecture of newly formed bone in PEC groups was superior to that of ACS groups. The bony tissue in groups 1 and 2 had higher BV/TV and mineralized area ratio when compared with groups 3 and 4. The superior trabecular structure of the new bone in PEC groups was observed when compared to ACS groups as demonstrated by superior trabecular thickness, higher trabecular number, and less separation. Within the PEC groups, 400 mg BMP-2 was as effective as 800 mg BMP-2 in inducing consistent inter-transverse fusion in this porcine posterolateral fusion model with no statistically significant difference in 3D microarchitecture parameters. The BV/TV, Tb.Th., and mineralized area ratio in group 2 were comparable if not superior to that in group 1. There was no compromise of bone quality and fusion rate despite dose reduction in PEC groups. The microarchitecture of the newly formed bone in group 2 appeared to be better than that in group 1. Furthermore, the localization of new bone within the scaffold in group 2 was superior to that in group 1 with minimal heterotopic bone formation. It seemed that with appropriate BMP-2 dosing (400 mg), PEC could achieve satisfactory fusion rates and good quality of new bone formation while concurrently minimizing ectopic bone formation. This was attributed to the capacity of PEC to retain BMP-2 molecules on the surface of the microbeads and further control the release of the bioactive molecule after implantation. 13 This result demonstrates that the microarchitecture and localization of the newly formed bone could be improved when BMP-2 was carried by PEC, which agrees with previous findings of PEC in both in vitro and in vivo small animal study. 13, 14, 28 There are several limitations in the present study. Firstly, the fusion assessment was only done once at eighth week after implantation. The observation time is relatively short and further observation might reveal more information. Besides, CT scans at different time points after surgery might allow us to compare the bone formation rate in different study groups. Secondly, the sample size of present study was small due to the limitation of the available large animals. Despite this, the findings of the present study are promising and calls for further investigations into this strategy.
In conclusion, PEC with BMP-2 achieved successful posterolateral fusion in porcine model. It enhanced the fusion efficiency of BMP-2 with reduction of heterotopic ossification. The microarchitecture of the newly formed bone was improved when BMP-2 was used in combination with PEC compared with ACS. The application of PEC carrier could enhance the efficacy and safety profile of BMP-2 in posterolateral fusion by localizing new bone formation and significantly reducing dose-and carrierrelated complications. Further clinical studies are warranted for translational purpose.
Key Points
BMP-2 delivered by heparin-based PEC was able to induce successful posterolateral fusion in porcine model. PEC could enhance the fusion efficacy of BMP-2 and reduce heterotopic ossification. The microarchitecture of the newly formed bone induced by BMP-2 with PEC was superior to that by BMP-2 with ACS.
